Tuesday, 6 October 2015

Arla buys ALKS 60.48: ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

ARISTADA is administered by a healthcare professional. Worldwide, it is estimated that one person in every 100 develops schizophrenia, which is one of the most serious types of mental illness. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. BST) on Tuesday, Oct. 6, 2015, through 5:00 p.m. The results of the phase 3 study were published in June 2015 by The Journal of Clinical Psychiatry , a peer-reviewed medical journal.


Cora:
As a long-acting injectable medicine, ARISTADA provides patients, clinicians and families the certainty that patients receive medication for this serious brain disorder.

Lorina:
Alkermes is preparing to launch ARISTADA immediately.

Macy:
ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection.

Collette:
This, though usually a good sign, quickly became overshadowed by the negative indicators, such as low scores, increasing shares outstanding, and bad financials.

Lakia:
At a first glance, the stock looks promising, growing consistently over the past three years.

Marjorie:
The more fields I tested against ALKS, the more I grew to dislike the stock.

Jessika:
ALKS scores a 2 out of 7, and its score has been steadily decreasing over the past three years.

Karolyn:
This score, a score out of 7, helps to indicate whether a company has a strong past and has the probability of going up, even slightly, in the future.

Luisa:
This past year, however, the company fell backwards, only having $11 million in cash flow and ultimately having a negative FCF/share.

Angelo:
At this point, the prospects for this company looked good and the share price began to surge.

Alkermes (NASDAQ:ALKS)
//stockhand.net/us/?q=nasdaq%3Aalks&id=722472

No comments:

Post a Comment